guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
TRANSCRIPT
Guideline
GUIDELINES FOR THE DIAGNOSIS AND THERAPY OF ADULT MYELODYSPLASTIC SYNDROMES
The myelodysplastic syndromes (MDS) represent a hetero-geneous group of haematopoietic disorders affecting pre-dominantly elderly individuals (median age 69 years). Theoverall disease incidence is about 4 per 100 000 populationbut this rises to > 30 per 100 000 in the over 70 year agegroup. The pathological processes underlying the haemato-logical abnormalities seen in MDS are:1. augmented apoptosis, leading to ineffective haematopoi-
esis and peripheral cytopenias;2. transformation to acute myeloid leukaemia (AML).
The precise relationship between these pathologicalprocesses remains uncertain but has important implicationsfor the design of new therapeutic strategies targeting one orthe other or indeed both.
METHODS
The guideline group was selected to include UK-based medicalexperts in the clinical management of MDS and to include arepresentative from a District General Hospital. The draftinggroup met on six occasions. Each group member wasallocated responsibility for preparation of a selected compo-nent of the first draft. Medline ⁄Pubmed was systematicallysearched from 1982. The Cochrane database was searchedbut contained no references to MDS. Meeting abstracts werenot included in the systematic search strategy. The Chairmansynthesized the draft components, which were revised byconsensus through meetings 3–6. No recommendations areincluded for which full consensus was not achieved. The draftguideline was reviewed by the Sounding Board and by theCommittee of the British Committee for Standards in Hae-matology, and comments incorporated where appropriate.Following further helpful peer-review by the British Journal ofHaematology, a final revision is now presented. Criteria usedto quote Levels and Grades of Evidence are outlined in Table I.A full guideline revision is planned for May 2005.
DIAGNOSIS
The diagnosis and classification of MDS remain dependenton the morphological examination of blood and bonemarrow cells. Diagnostic criteria should ideally distinguishMDS from reactive conditions causing dysplastic haemato-poiesis and from other clonal myeloid disorders. Theminimum clinical assessment and laboratory investigationrequired for the definitive diagnosis of cases of suspected
MDS is shown in Table II. Practical issues regarding thediagnosis of MDS include the following:1. Should every patient have a bone marrow aspirate? A
bone marrow aspirate is usually necessary to make aconfident diagnosis and to provide important prognosticinformation. This may not, however, be necessary inelderly patients in whom a definitive diagnosis of MDSwould not alter management or whose poor generalhealth precludes active treatment.
2. Should every patient have a bone marrow trephine?Bone marrow histology complements the morphologicalinformation obtained from a marrow aspirate and hencea trephine biopsy should be performed in all cases ofsuspected MDS in whom bone marrow examination isindicated. Diagnostic certainty can be improved byfeatures such as the presence of megakaryocyte dyspla-sia, while disordered marrow architecture such ascentral clustering of immature myeloid cells (abnormallocalization of immature precursors or ALIPs) is anadverse prognostic marker (Tricot et al, 1984). Theassessment of cellularity and fibrosis define morphologi-cal variants, with the identification of hypocellular MDSof particular therapeutic importance (see below) (Mijovic& Mufti, 1998).
3. Should all patients have cytogenetic analysis? A chro-mosome abnormality confirms the presence of a clonaldisorder aiding the distinction between MDS and reactivecauses of dysplasia, and in addition has major prognosticvalue. Cytogenetic analysis should therefore be per-formed for all patients in whom a bone marrowexamination is indicated.
4. What are the minimal morphological diagnostic criteriafor MDS? Minimal diagnostic criteria are not clearlydefined in MDS. Difficulties arise because a variety ofreactive disorders are associated with dysplastic mor-phology and mild dysplastic features are frequently seenin the marrow of healthy people with normal bloodcounts (Bain, 1996; Ramos et al, 1999).
The following are recommended to increase the reliabilityof diagnosing MDS.a) At least 200 marrow cells and 20 megakaryocytes
should be evaluated where possible.b) Dysplastic features should be present in > 10% of
marrow cells (Kouides & Bennett, 1996).c) Particular attention should be given to the presence of
pseudo-pelger neutrophils, ring sideroblasts, micro-megakaryocytes and increased blasts as these abnormal-ities correlate most strongly with the presence of clonalmarkers in MDS and show least interobserver variation(Kuriyama et al, 1986; Ramos et al, 1999).
Correspondence: Dr David Bowen, Molecular and Cellular Pathol-
ogy, Ninewells Hospital, Dundee, DD1 9SY, UK. E-mail: d.t.bowen@
dundee.ac.uk
British Journal of Haematology, 2003, 120, 187–200
� 2003 Blackwell Publishing Ltd 187
d) The assessment of neutrophil granularity is criticallydependent on optimal staining and it is unwise to base adiagnosis of MDS solely on the presence of neutrophilhypogranularity in the absence of other dysplasticfeatures.
It is recognized that the definitive diagnosis of early refractoryanaemia may be difficult, for example in patients with a singleisolated cytopenia or isolated macrocytosis. If the morphological
diagnosis remains uncertain, it is recommended that the patientbe reviewed regularly in the haematology clinic with repeat bloodcount and morphological assessment at appropriate intervals.5. Overlap syndromes. At least three overlap syndromes are
recognized namely: fibrotic MDS (Mijovic & Mufti, 1998),MDS with thrombocytosis (Harris et al, 1999) andhypoplastic MDS (Tuzuner et al, 1994, 1995). Presently,only the latter requires a distinctive therapeuticapproach and as such is important to distinguish fromaplastic anaemia.
Hypocellular MDS versus aplastic anaemiaThe diagnosis of hypocellular MDS is of importance, aspreliminary data suggest that the response to immunosup-pressive therapy is higher than in cases of MDS with normo-or hypercellular marrows. A trephine may be consideredhypocellular if cellularity is < 30% in individuals youngerthan 60 years or < 20% in those over 60 years of age(Tuzuner et al, 1994, 1995). The diagnosis of myelodysplasiarequires the presence of dysplastic features in megakaryo-cytes and ⁄ or myeloid cells or an excess of blasts. Erythroiddysplasia is found in aplastic anaemia and cannot be usedalone to distinguish MDS from AA. The presence of anabnormal karyotype strongly favours the diagnosis of MDSbut cases of aplastic anaemia with an abnormal karyotypewithout morphological features of MDS and with a low risk oftransformation to MDS or AML have been described.
CLASSIFICATION OF MDS
The World Health Organization (WHO) recently publishedproposals for a new classification of MDS to supersede the
Table I.
(A) Levels of evidence.
Level Type of evidence
Ia Evidence obtained from meta-analysis of randomized controlled trials.
Ib Evidence obtained from at least one randomized controlled trial.
IIa Evidence obtained from at least one well-designed controlled study without randomization.
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case
control studies.
IV Evidence obtained from expert committee reports or opinions and ⁄ or clinical experiences of respected authorities.
(B) Grades of recommendation.
Grade Evidence level Recommendation
A Ia, Ib Required – at least one randomized controlled trial as part of the body of literature of overall good quality and
consistency addressing specific recommendation.
B IIa, IIb, III Required – availability of well-conducted clinical studies but no randomized clinical trials on the topic of
recommendation.
C IV Required – evidence obtained from expert committee reports or opinions and ⁄ or clinical experiences of
respected authorities.
Indicates absence of directly applicable clinical studies of good quality.
Table II. Evaluation of suspected MDS.
History
Prior exposure to chemotherapy ⁄ radiation
Family history of MDS ⁄AML
Recurrent infections or bleeding ⁄ bruising
Examination
Pallor ⁄ infection ⁄ bruising
Splenomegaly
Full blood count
Macrocytosis, cytopenia(s), neutrophilia, monocytosis, thrombo-
cytosis
Blood film
Assay of serum ferritin, vitamin B12 and folate levels
Bone marrow aspirate
Bone marrow trephine biopsy
Bone marrow cytogenetic analysis
Exclusion of reactive causes of dysplasia
Megaloblastic anaemia
Human immunodeficiency virus infection
Alcoholism
Recent cytotoxic therapy
Severe intercurrent illness
188 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
French–American–British (FAB) classification (Bennett et al,1982). The new classification is based on a combination ofmorphology, karyotype and clinical features (Harris et al,1999), and potential problems with the adoption of the newclassification have recently been summarized (Greenberget al, 2000). The final classification has now been published(Jaffe et al, 2001) and is in the process of independentvalidation (Germing et al, 2000a; Nosslinger et al, 2001).Given the limited experience with the use of this newclassification to date, this guideline will use the more familiarFAB terminology (Bennett et al, 1982).
PROGNOSTIC SCORING SYSTEMS
All patients diagnosed with MDS have a reduced lifeexpectancy compared with age- and sex-matched normalcontrols, regardless of disease subtype. This difference isparticularly marked in younger patients (£ 60 years) andthose with �high-risk� disease. (Morel et al, 1996). While theFAB ⁄WHO classification systems are themselves of signifi-cant prognostic value, scoring systems employing objectiveparameters allow improved reproducibility for clinicaldecision-making but also for clinical trials and biologicalresearch in MDS patients. A series of different prognosticscoring systems have been developed since the originalBournemouth score (Mufti et al, 1985). The latest of theseis the International Prognostic Scoring System (IPSS)(Greenberg et al, 1997), which has improved prognosticpower compared with previous scoring systems, namely theSanz (Sanz et al, 1989) and Lille (Morel et al, 1993) scores.The IPSS is a multivariate analysis of patient characteristics
derived from a pool of 816 MDS patients who had beenincluded in the cohorts used to derive previous scoringsystems (Table III). A cautionary note is that the patientcohort analysed by the IPSS group were largely untreatedand may therefore include the MDS patients with poorestperformance status and therefore worst outlook. The IPSShas also excluded chronic myelomonocytic leukaemia(CMML) patients with a white blood cell count(WBC) > 12 · 109 ⁄ l, considering this group as myelopro-liferative rather than myelodysplastic. The IPSS score iscomputed from three parameters, namely bone marrowblast percentage, bone marrow cytogenetics and number oflineages with cytopenia, in decreasing order of prognosticpower. While this guideline advocates bone marrow cyto-genetic analysis for all MDS patients in whom a bonemarrow examination is deemed appropriate, we accept thatthis is not always technically successful. In this raresituation, an alternative scoring system most familiar tothe clinician will be required, such as the Sanz (Sanz et al,1989) or Bournemouth (Mufti et al, 1985) scores. Themethodology used to derive the Sanz score is more rigorousand provides greater prognostic discrimination than theBournemouth score, at least in patients with > 5% blasts.
While the use of prognostic scoring systems is advocated,it must be recognized that even within each prognosticgroup the emergence of distinct clinical entities, which havedifferent prognoses, is inevitable. Examples of these includepure sideroblastic anaemia (Germing et al, 2000b) andperhaps the �5q– syndrome�, both of which are associatedwith an excellent prognosis and a low rate of transforma-tion to acute leukaemia.
Table III.
(A) International Prognostic Scoring System: derivation of patient score.
Score value
0 0Æ5 1 1Æ5 2
BM blasts percentage < 5 5–10 11–20 21–30
Karyotype Good Intermediate Poor
Cytopenias 0 ⁄1 2 ⁄3
Score for risk groups are as follows: Low 0; INT-1 0Æ5–1Æ0; INT-2 1Æ5–2Æ0; High ‡ 2Æ5. Karyotype:
Good, normal, –Y, del(5q), del(20q); Poor, complex (‡ 3 abnormalities) or chromosome 7 anomalies;
Intermediate, other abnormalities. Cytopenias defined as haemoglobin concentration < 10 g ⁄ dl, neu-
trophils < 1Æ8 · 109 ⁄ l and platelets < 100 · 109 ⁄ l.
(B) Median survival: IPSS score.
Median survival (years)
£ 60 years
(n ¼ 205)
> 60 years
(n ¼ 611)
£ 70 years
(n ¼ 445)
> 70 years
(n ¼ 371)
Low (n ¼ 267) 11Æ8 4Æ8 9 3Æ9INT-1 (n ¼ 314) 5Æ2 2Æ7 4Æ4 2Æ4INT-2 (n ¼ 176) 1Æ8 1Æ1 1Æ3 1Æ2High (n ¼ 59) 0Æ3 0Æ5 0Æ4 0Æ4
Guideline 189
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
MANAGEMENT OF MYELODYSPLASTICSYNDROMES
It is recommended that, where possible, managementdecisions be based upon the patient’s IPSS score. It isimportant that the IPSS score is calculated during a stableclinical state and not, for example, during a florid infectiveinitial presentation. Management decisions should be takenwith the informed involvement of the patient and, to aidthis, information booklets are available from the LeukaemiaResearch Fund and the Myelodysplastic Syndromes Foun-dation. The guideline will critically review individual thera-peutic modalities designed to improve the clinical problemsspecific to an individual patient with MDS, and willconclude with recommendations for management strategiesdriven by the patient’s IPSS score and the overall clinicalpicture. It is, however, important to stress that mostrecommendations are made on the basis of a very limitedevidence base for the efficacy of interventional and non-interventional therapy in MDS. Most papers reportinginterventional therapy describe relatively small cohorts ofpatients and only one (small) placebo-controlled trial isavailable. Criteria for defining therapeutic response are alsohighly variable between studies. The recent publication ofstandardized response criteria for therapeutic studies inMDS patients (Cheson et al, 2000) may facilitate theinterpretation of how clinically meaningful new therapeuticinterventions in MDS really are.
Supportive care: principlesSupportive care remains the most important aspect ofmanagement for patients with good prognosis MDS andthose with poor prognosis disease whose age or performancestatus precludes them from receiving more intensive formsof therapy. The aim is to reduce morbidity and mortalitywhile at the same time providing an acceptable quality oflife. However, grade A and grade B evidence for the
effectiveness of supportive care in patients with myelodyspl-asia is absent and is unlikely to ever be obtainable. Forpatients with good prognosis MDS, it is often feasible toundertake a period of observation without needing tointroduce specific therapy. Where possible, this �wait andwatch� approach to management may also be useful forpatients with more advanced MDS, allowing one to appraisethe stability of the disease process and to assess the need tointroduce treatment.
Management of anaemiaAt presentation, up to 80% of cases of MDS will have ahaemoglobin concentration < 10 g ⁄ dl (Sanz et al, 1989).Anaemia in MDS is usually due to ineffective erythropoiesisbut other factors that may accentuate anaemia, e.g.nutritional deficiencies, haemorrhage, haemolysis andinfection, should be sought and treated as appropriate.Chronic anaemia is seldom life threatening but can lead tosignificant morbidity and is therefore important in relationto quality of life issues. Figure 1 outlines a flow chart for themanagement of the anaemic MDS patient.
Red cell transfusion and iron chelation therapy. The use ofred cell transfusion should be considered in any patient withsymptoms of anaemia. It is not possible to ascribe a singlehaemoglobin concentration as being the optimal level belowwhich red cell support should be dispensed and eachindividual case needs to be considered separately (Murphyet al, 2001). Studies in cancer patients have demonstrated apositive correlation between increases in the haemoglobinlevel (with recombinant Erythropoietin therapy) andimprovements in quality of life (QOL) (Glaspy et al, 1997;Demetri et al, 1998).
Recommendations for iron chelation treatment in mye-lodysplasia are based on limited data (evidence grade B,level III). Iron chelation should be considered once a patienthas received 5 g iron (approximately 25 units of red cells)but only in patients for whom long-term transfusion
Fig 1. Guidelines for the management of symptomatic anaemia in MDS patients.
190 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
therapy is likely, such as those with pure sideroblasticanaemia or the �5q– syndrome�. Desferrioxamine20–40 mg ⁄ kg should be administered by 12 h subcuta-neous infusion 5–7 d per week. Audiometry and ophthal-mology review are essential prior to commencement ofdesferrioxamine. The target ferritin concentration should be< 1000 lg ⁄ l; if the ferritin concentration falls below< 2000 lg ⁄ l, the dose of desferrioxamine should be reducedand should not exceed 25 mg ⁄ kg. Vitamin C 100–200 mgdaily should be commenced after 1 month of desferriox-amine therapy. Vitamin C should be taken when theinfusion is set up. Repeat audiometry and ophthalmologyreview should be performed at least annually. The use oftwice daily subcutaneous bolus injections of desferrioxa-mine (Franchini et al, 2000) may be considered whereinfusions are not tolerated, but the common practice ofadding a single dose of desferrioxamine at each transfusionepisode has no basis and should be discouraged. At present,deferiprone (L1) cannot be recommended for routine use inthis group of patients, given the lack of published data inMDS patients and continuing concerns about both efficacyand safety (Pippard & Weatherall, 2000).
Erythropoietin (EPO) + ⁄ – granulocyte colony-stimulatingfactor (G-CSF). Many studies have clearly demonstratedthat EPO ± G-CSF can increase haemoglobin concentra-tion and reduce ⁄ eliminate red cell transfusion in selectedMDS patients, and a summary outline of these is providedin Tables IVA and B. These studies were small cohortstudies (< 120 patients in each) and only one (small)placebo-controlled randomized study (of EPO therapyalone) has been reported (Italian Cooperative StudyGroup, 1998). Given the small size of this placebo-controlled trial of EPO therapy alone (87 patients), thegrade of recommendation for EPO therapy alone shouldbe considered as grade A ⁄B (level Ib ⁄ IIa). The evidencefor efficacy of the combination of EPO + G-CSF therapy isgrade B (level IIa ⁄ IIb).
These studies suggest that patients with refractoryanaemia with ringed sideroblasts (RARS) are more likelyto respond to the combination of EPO + G-CSF (HellstromLindberg et al, 1997, 1998). Patients with refractoryanaemia (RA) or RA with excess blasts (RAEB) mayrespond well to EPO alone, though a proportion will benefitfrom the addition of G-CSF (Hellstrom Lindberg, 1995,Hellstrom-Lindberg et al, 1998; Italian Cooperative StudyGroup, 1998; Mantovani et al, 2000). Overall there issufficient evidence for the efficacy of EPO ± G-CSF therapyin appropriately selected patients. It is recommended thatthose patients with RA and RAEB [not eligible forchemotherapy ⁄ stem cell transplantation (SCT): see later]who are symptomatic of anaemia, with no ⁄ low transfusionrequirement (< 2 units ⁄month) and a basal EPO level ofless than 200 U ⁄ l (measured at the haemoglobin nadir intransfusion-dependent patients) be considered for a trial ofEPO alone at a dose of 10 000 units daily for 6 weeks(Hellstrom Lindberg, 1995). For non-responders, consid-eration should be given to either the addition of dailyG-CSF, doubling the dose of EPO, or both for a further6 weeks. The dose of G-CSF should be escalated weekly
from 75 lg, to 150 lg to 300 lg (multiple sampling fromsingle vials kept at 4�C) to maintain the WBC between 6and 10 · 109 ⁄ l. In responding patients, once the maxi-mum response has been reached, the G-CSF can bereduced to thrice weekly and the EPO to 5 d then 4 d to3 d per week at 4 weekly intervals to the lowest dose thatretains response.
For patients with RARS, symptomatic anaemia, basalEPO levels of < 500 U ⁄ l and a transfusion requirement ofless than 2 units per month, it is recommended thatcombined therapy with EPO and G-CSF is used from theoutset (Hellstrom Lindberg et al, 1997). Dosing recommen-dations are as for RA ⁄RAEB with consideration given todose escalation of EPO at 6 weeks in non-responders for afurther 6 weeks.
While there are no published data demonstrating thatgrowth factor therapy improves QOL, extrapolation fromcancer patients treated with EPO suggests that this is likelyto be the case and that maintenance of a stable augmentedhaemoglobin concentration may be preferable to the cyc-lical fluctuations of red cell transfusion programmes (Bowen& Hellstrom-Lindberg, 2001). It should also be noted thatthere are a lack of survival data and of quality pharmaco-economic data to support the use of haematopoietic growthfactor therapy. We would, therefore, encourage continuingrandomized-controlled trials of EPO ± G-CSF, which addressthe issues of QOL, survival advantage and pharmaco-economics.
Immunosuppression. Two groups have demonstrated theefficacy of horse anti-lymphocyte globulin (ALG) in raisingthe blood counts in a proportion of patients with MDS,although each cohort reported is small, namely n ¼ 25(Molldrem et al, 1997) [updated in abstract form to n ¼ 60(Barrett et al, 1998)] and n ¼ 12 (Killick et al, 1999)patients respectively. ALG seems to be more effective inhypoplastic MDS and in patients with a paroxysmalnocturnal haemoglobinuria (PNH) clone (Dunn et al,1999), but also induces significant improvements innormo- and hypercellular patients with low-risk MDS(IPSS £ INT-1). Preliminary data suggest that responses,when achieved, are durable and prolonged (Barrett et al,1998). Most clinically meaningful responses are in theerythroid lineage but bi- and trilineage responses are seen.Similar responses have been observed with cyclosporin A(Jonasova et al, 1998), with higher response rates also inhypocellular MDS. Anecdotal reports of corticosteroid-responsive MDS exist but this therapy cannot at presentbe recommended. The data support a recommendation for atrial of immunosuppressive therapy with ALG at least forpatients with hypoplastic MDS (evidence grade B, level IIb).
Other agents. Therapeutic agents with limited therapeuticvalue that are not routinely recommended are outlined inTable V.
Management of thrombocytopeniaBleeding is a common and potentially serious complicationof MDS. Both the degrees of thrombocytopenia and plateletfunctional abnormalities may contribute to this. The role ofplatelet transfusions in MDS patients should be based on the
Guideline 191
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Ta
ble
IV.
(A)
Tri
als
of
ery
thro
po
ieti
na
lon
ein
MD
S.
Nu
mb
ero
fp
ati
ents
Res
ult
sC
om
men
ts
Met
aan
aly
ses
Hel
lstr
om
Lin
db
erg
(19
95
)2
05
fro
m1
7tr
ials
16
%o
ver
all
resp
on
seR
esp
on
sep
ara
met
ers
sta
nd
ard
ized
for
all
incl
ud
edst
ud
ies.
Res
po
nse
rate
sco
mp
are
dw
ith
Ma
nn
–Wh
itn
eyU
test
(ser
um
EP
Oco
nce
ntr
ati
on
bet
wee
nsu
bg
rou
ps)
or
Fis
her
’sex
act
test
(ca
teg
ori
es).
Hig
her
resp
on
sera
tes
if:
seru
mE
PO
<2
00
U⁄l,
no
n-R
AR
S
FA
Bty
pe,
no
n-t
ran
sfu
sio
nd
epen
den
t
Ro
dri
gu
ezet
al(1
99
4)
(ab
stra
cto
nly
;S
pa
nis
h)
11
5fr
om
10
stu
die
s2
3Æ5
%re
spo
nse
Hig
her
resp
on
sefo
rR
AE
B.
No
rela
tio
nsh
ipto
EP
Ole
vel
or
tra
nsf
usi
on
req
uir
emen
t.
Pos
t-m
eta
anal
yse
s(s
tudi
esw
ith
>1
0pa
tien
ts)
Ita
lia
nC
oo
per
ati
ve
Stu
dy
Gro
up
(19
98
)8
71
4⁄3
8vs
4⁄3
7re
spo
nd
ers;
(P¼
0Æ0
07
)
infa
vo
ur
of
EP
O
Ra
nd
om
ized
do
ub
le-b
lin
dp
lace
bo
-co
ntr
oll
edst
ud
yo
fE
PO
inlo
w-r
isk
MD
S.
Res
po
nse
ass
esse
da
t8
wee
ks.
FA
Bty
pe¼
RA
,b
asa
lE
PO
lev
el<
20
0U⁄l,
no
n-t
ran
sfu
sed
,
all
pre
dic
ted
for
resp
on
se
Sta
siet
al(1
99
7a
)4
31
6Æ7
%(C
R+
PR
)6
pa
tien
tsre
spo
nd
edto
do
sees
cala
tio
nfr
om
15
0l⁄k
g3·
per
wee
kto
30
0l⁄k
g3·
per
wee
k.
Ery
thro
idh
yp
erp
lasi
aa
nd
circ
ula
tin
ger
yth
roid
bu
rst-
form
ing
un
its
bes
tp
red
icto
rso
fre
spo
nse
Sta
siet
al(1
99
7b
)2
5(n
ote
?sa
me
pa
tien
tsa
sa
bo
ve)
4C
R,
5P
RR
esp
on
der
sh
ad
low
erse
rum
con
cen
tra
tio
n
of
tum
ou
rn
ecro
sis
fact
or-
aD
iR
aim
on
do
etal
(19
96
)1
2w
ith
RA
on
ly,
no
rma
lW
BC
an
d
pla
tele
tsa
nd
sho
rtd
ura
tio
no
fd
isea
se
7(5
8Æ3
%)
CR
,2
PR
Hig
hly
sele
cted
,m
ild
case
so
fR
A
Ro
seet
al(1
99
5)
11
62
8%
Au
tho
rsa
llfr
om
R.W
.Jo
hn
son
Ph
arm
ace
uti
cal
Co
mp
an
y.
RA
an
dR
AR
Sre
spo
nd
ed.
Ser
um
EP
O<
10
0U⁄l
pre
dic
ted
for
resp
on
se(5
4%
of
RA
wit
hlo
wE
PO
resp
on
ded
)
CR
,co
mp
lete
resp
on
seP
R,
pa
rtia
lre
spo
nse
.
(B)
Tri
als
of
ery
thro
po
ieti
np
lus
G-C
SF
inM
DS
.
Nu
mb
ero
fP
ati
ents
Res
ult
sC
om
men
ts
Ma
nto
va
ni
etal
(20
00
)3
36
1%
ery
thro
idre
spo
nse
at
12
wee
ks
80
%er
yth
roid
resp
on
sea
t3
6w
eek
s
12⁄1
7re
spo
nd
ers
at
12
wee
ks
an
d1
4⁄2
0
resp
on
der
sa
t2
0w
eek
sh
ad�g
oo
d
ery
thro
idre
spo
nse�
na
mel
yin
dep
end
ent
of
red
cell
tra
nsf
usi
on⁄s
ust
ain
edin
crea
sein
Hb
>2
g⁄d
l.
Rem
ach
aet
al(1
99
9)
32
Ery
thro
idre
spo
nse
in5
0%
(12
pa
tien
tsC
Ra
nd
4P
R).
13
resp
on
der
sm
ain
tain
edre
spo
nse
on
trea
tmen
tfo
r2
yea
rs.
192 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Hel
lstr
om
Lin
db
erg
etal
(19
97
)D
evel
op
men
to
fp
red
icti
ve
mo
del
fro
mH
ells
tro
m-L
ind
ber
get
al
(19
98
)a
nd
Neg
rin
etal
(19
96
)
36
%re
spo
nse
.
Med
ian
du
rati
on
of
resp
on
se¼
11
–2
4m
on
ths
Inm
ult
iva
ria
tea
na
lysi
s,se
rum
EP
Ole
vel
sa
nd
init
ial
tra
nsf
usi
on
nee
dw
ere
sig
nifi
can
tp
red
icto
rs
of
resp
on
se.
Pre
dic
tiv
esc
ore
for
resp
on
sed
evel
op
ed
by
log
-lik
elih
oo
da
nd
log
isti
cre
gre
ssio
na
na
lyse
s.
Gro
up
1¼
74
%p
rob
ab
ilit
yo
fre
spo
nse
,G
rou
p
2¼
23
%p
rob
ab
ilit
yo
fre
spo
nse
,G
rou
p3¼
7%
pro
ba
bil
ity
of
resp
on
se
Hel
lstr
om
-Lin
db
erg
etal
(19
98
)5
0in
ran
do
miz
edst
ud
yO
ver
all
resp
on
sera
tew
as
38
%.
Res
po
nse
rate
sin
the
two
arm
sw
as
iden
tica
l.
Med
ian
surv
iva
l¼
26
mo
nth
s,le
uk
aem
ic
tra
nsf
orm
ati
on
28
%.
Med
ian
du
rati
on
of
resp
on
sein
20
lon
g-t
erm
ma
inte
na
nce
pa
tien
ts¼
24
mo
nth
s.
Inra
nd
om
ized
stu
dy
:
Arm
A¼
G-C
SF
for
4w
eek
sfo
llo
wed
by
com
bin
ati
on
for
10
wee
ks.
Arm
B¼
EP
Ofo
r8
wee
ks
foll
ow
edb
yth
e
com
bin
ati
on
for
10
wee
ks.
Res
po
nse
rate
sfo
rR
A,
RA
RS
,R
AE
Bw
ere
20
%,
46
%,
37
%re
spec
tiv
ely
.
Neg
rin
etal
(19
96
)5
55
3(9
6%
)h
ad
an
eutr
op
hil
resp
on
se.
Res
po
nse
pre
dic
ted
by
low
seru
mE
PO
lev
el,
44
pa
tien
tsev
alu
ate
dfo
ra
ner
yth
roid
resp
on
se
an
d2
1(4
8%
)h
ad
are
spo
nse
.
81
%o
fth
ese
resp
on
der
sm
ain
tain
edth
eir
resp
on
se
hig
her
ab
solu
teb
asa
l
reti
culo
cyte
cou
nts
an
dn
orm
al
cyto
gen
etic
s
at
stu
dy
entr
y
du
rin
ga
n8
-wee
km
ain
ten
an
cep
ha
se.
Ima
mu
raet
al(1
99
4)
10
No
resp
on
ses
iner
yth
roid
or
pla
tele
tsfo
llo
win
g
10
wee
ks
of
trea
tmen
t.
80
%h
ad
an
eutr
op
hil
resp
on
se
1d
ela
yed
ery
thro
idre
spo
nse
foll
ow
ing
cess
ati
on
of
trea
tmen
t.
Co
nsi
der
ab
lyh
igh
erd
ose
so
fG
-CS
F
(in
tra
ven
ou
s)th
an
ino
ther
stu
die
s.
Hel
lstr
om
Lin
db
erg
etal
(19
93
)2
28
(38
%)
sho
wed
asi
gn
ifica
nt
resp
on
sein
Hb
Les
sa
dv
an
ced
pa
ncy
top
enia
,lo
wer
lev
els
of
seru
m
EP
Oa
nd
rin
gsi
der
ob
last
sp
red
icte
dfo
rre
spo
nse
.
Neg
rin
etal
(19
93
)2
41
0(4
2%
)h
ad
an
ery
thro
idre
spo
nse
Lo
wp
retr
eatm
ent
EP
Ole
vel
so
nly
pre
dic
tor
for
resp
on
se.
Guideline 193
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Royal College of Physicians of Edinburgh Consensus Con-ference Statement (Ancliff & Machin, 1998). Antifibrinolyticagents (grade C, level IV) and Danazol (grade B, level IIb)are occasionally useful but cannot be routinely recom-mended.
Management of infectionProphylactic. There are no published data to support the
routine use of antibacterial or antifungal prophylaxis inneutropenic MDS patients. Consideration may be given tothe use of prophylactic low-dose G-CSF therapy in severely
Table V. Therapeutic agents of limited value for the treatment of anaemia in MDS.
Agent
Level of
evidence
Grade of
evidence Recommendation Comments
Single agent
13 cis retinoic acid (13 CRA) Ib A Not recommended Although an early study suggested improved
survival with 13 CRA compared with
supportive care (Clark et al, 1987), a subsequent
randomized placebo-controlled trial in 68 patients
had only three minor responders (2 placebo vs 1 13
CRA) (Koeffler et al, 1988). Several non-randomized
studies have also showed low (< 20%) short-term
response rates (Picozzi et al, 1986; Kerndrup et al,
1987; Bourantas et al, 1995).
All-trans retinoic acid IIb B Not recommended Small non-randomized studies report low frequency
and only transient response (Visani et al, 1995).
9-cis retinoic acid IIb B Not recommended A small multicentre study showed 17% responses
(5 of 30; 1 complete and 4 minor) with poor
tolerability at the doses used (Hofmann et al 2000).
Vitamin D3 IIb B Not recommended Small cohort studies only (all < 20 patients)
with variable doses and responses. Occasional
patients achieved transfusion independence
(< 20%) (Mellibovsky et al, 1998). Higher doses
limited by hypercalcaemia (Koeffler et al, 1985).
Interferons IIb B Not recommended Small cohort studies only (mostly < 20 patients)
of either a-interferon (Elias et al, 1987; Galvani et al,
1988; Gisslinger et al, 1990; Aul et al, 1991; Nand
et al, 1992; Petti et al, 1996) or c interferon
(Stone et al, 1993). Low response rates
and generally high toxicity.
Amifostine IIb B CRP Haematopoietic stimulatory activity demonstrated
in cohort studies of intermittent dosing (List et al,
1997; Grossi et al 2000) but not continuous
schedule (Bowen et al, 1998). Responses are
transient and high side-effect profile ⁄ cost.
Pyridoxine III C Not recommended No trials reported; anecdotal responses in patients
with RARS but these most likely represent
late-onset congenital sideroblastic anaemia
rather than MDS (Cotter et al, 1995).
Combination therapy
Retinoids + low-dose
Cytosine arabinoside
IIb B Not recommended Many small cohort studies with variable response
rates but none comparing combinations with single
agent in randomized trials; comprehensively
reviewed in Santini & Ferrini (1998).
Pentoxyfilline ⁄Ciprofloxacin ±
Dexamethasone ± Amifostine
IIb B CRP Small cohort study showed no response
to Pentoxyfilline + Ciprofloxacin combination in
high-risk patients (Nemunaitis et al, 1995). Two
small cohort studies (12 and 29 patients) treated
with Pentoxyfilline + Ciprofloxacin + Dexamethasone
(PCD) (Novitzky et al, 2000) and PCD + Amifostine
(Raza et al, 2000) respectively. Clinically meaningful
erythroid responses in up to 30% patients.
Unclear which drugs were active.
CRP, to be used in defined clinical research protocols only.
194 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
neutropenic patients to maintain the neutrophil count> 1 · 109 ⁄ l (grade B, level IIb) (Negrin et al, 1996).
Therapeutic. Neutropenic sepsis in MDS patients should betreated with intravenous antibiotics as for other patientswith neutropenia (e.g. post chemotherapy).
Non-intensive chemotherapyThere is insufficient evidence to recommend routine use oflow-dose chemotherapy. Many relatively small studies arereported but none have demonstrated clear benefit in termsof survival or improved quality of life (Table VI). Of theseagents, 5-aza-2-deoxycytidine (and the parent compound5-azacytidine) shows perhaps the greatest promise.
Chronic myelomonocytic leukaemiaCMML often has a myeloproliferative component, andcytoreductive chemotherapy is frequently indicated.Hydroxyurea is considered the standard treatment forCMML, in preference to oral etoposide (evidence grade A,level Ib) (Wattel et al, 1996).
Intensive chemotherapy ⁄ stem cell transplantationFor the small number of eligible patients, allogeneic stem celltransplantation results in long-term event-free survival (EFS)in 32–54%. It is recommended that clinicians discuss allpatients eligible for stem cell transplantation with their localtransplant unit. Factors associated with improved outcomefollowing transplantation include younger age, shorterdisease duration, human leucocyte antigen-compatibility, primary MDS, < 10% blasts, good-risk cytogenetics(Anderson et al, 1993, 1996; Sutton et al, 1996; Deeg et al,2000). IPSS score is also a strong predictor of outcome, with5-year EFS of 60%, 36% and 28% in Low ⁄ INT-1, INT-2 andhigh-risk categories (Appelbaum & Anderson, 1998). Trans-plant-related mortality (TRM) for ablative allogeneic trans-plant is 40% in most studies, although the probable evolutiontowards non-ablative transplant approaches will reduce this.
Early indications are that autologous SCT may also prolongsurvival though stem cell mobilization is problematic inmany cases (de Witte et al, 1997). A small group of patientswho may benefit from intensive chemotherapy alone can alsobe identified.
IPSS Low. Neither intensive chemotherapy nor stem celltransplantation can currently be recommended for thisgroup whose median survival without treatment is4Æ8 (> 60 years))11Æ8 years (< 60 years) (Greenberg et al,1997).
IPSS Int-1. All patients < 65 years should be assessed forfitness ⁄ eligibility for allogeneic SCT as soon as possible afterdiagnosis, as SCT outcome is improved if performed early(Anderson et al, 1996). If eligible and a sibling donor isavailable, it is recommended that patients < 50 years areoffered ablative allogeneic SCT (evidence grade B, level IIb)and patients > 50 < 65 years are considered for non-ablative allogeneic SCT, within clinical trials where avail-able (evidence grade C, level IV). Patients with no siblingdonor, but with an unrelated donor should also beconsidered for ablative unrelated-donor SCT (< 40 years,evidence grade B, level III) or non-ablative unrelated-donorSCT within clinical trials (> 40 years, evidence grade C,level IV), though the TRM from these procedures remainshigh. Intensive cytoreductive chemotherapy prior to SCT isnot recommended for this group (evidence grade B, levelIIb).
Patients > 65 years or < 65 years and not suitable forSCT should be offered supportive care and ⁄ or considered forgrowth factor therapy (e.g. EPO). Recommendations for themanagement of IPSS INT-1 MDS patients £ 65 years areoutlined in Fig 2.
IPSS INT-2 ⁄HighChemotherapy plus SCT. All patients < 65 years should
again be considered as to fitness ⁄ eligibility for stem celltransplantation early after diagnosis. In this group of
Table VI. Non-intensive chemotherapeutic agents.
Agent
Level of
evidence
Grade of
evidence Recommendation Comments
Low-dose cytosine
arabinoside (LDAC)
Ib A Not recommended Two large studies of predominantly high-risk MDS patients.
Randomized study versus supportive care (141 patients)
showed no survival advantage and higher toxicity for
LDAC (Miller et al, 1992). Cohort study (n ¼ 102)
(Hellstrom Lindberg et al, 1992) demonstrated 29% �significant�and clinically meaningful responses. These and most smaller
studies showed responses usually of short duration.
5-aza-2-deoxycytidine IIb B CRP One moderate sized cohort study (n ¼ 66) of IPSS INT I ⁄ II and
High-score patients reported a 49% response rate of 31 weeks
median duration (Wijermans et al, 2000).
Melphalan IIb B CRP Two small cohort studies [n ¼ 21 (Omoto et al, 1996) and
n ¼ 14 (Denzlinger et al, 2000)] reported clinically meaningful
responses in selected patients; hypocellular RAEB ⁄ t with a
normal karyotype.
CRP, to be used in defined clinical research protocols only.
Guideline 195
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
high-risk patients, stem cell transplantation should only beconsidered for those responding to remission inductionchemotherapy (complete ⁄ good partial response) as theoutcome for non-responding patients is very poor (evidencegrade B, level IIb) (Sutton et al, 1996; Anderson et al, 1997;Nevill et al, 1998). For patients < 65 years, eligible for SCTand responding to chemotherapy, recommendations for SCTconsolidation are outlined in Fig 3. Large cohort studies areavailable for the assessment of ablative sibling and unrelat-ed allogeneic SCT but the role of autologous and non-
ablative SCT is yet to be clearly defined. Nevertheless, TRMis lower for both modalities and preliminary evidencesuggests that both will have a future role (de Witte et al,1997; Slavin et al, 1998).
Chemotherapy alone. Both patients > 65 years and those< 65 years who are ineligible for stem cell transplanta-tion should be considered for intensive chemotherapyalone. There have been no prospective randomized,controlled trials evaluating outcome following intensivechemotherapy compared with supportive care alone in
Fig 3. Guidelines for SCT in the management of IPSS INT-2 ⁄high MDS patients aged £ 65 years.
Fig 2. Guidelines for the management of IPSS INT-1 MDS patients aged £ 65 years.
196 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
MDS. Cohort studies suggest that of all high-risk MDSpatients (‡ INT-2), those with RAEB in transformation(RAEB-t, 20–30% marrow blasts) and lacking anindependent adverse risk factor [karyotype, age, perfor-mance status, length of antecedent haematologicaldisorder (Estey et al, 1997)] respond best to intensive�AML-type� chemotherapy (evidence grade B, level IIb)(Wattel et al, 1997). Thus, intensive chemotherapy aloneis recommended for consideration in these patients. Nochemotherapy combination is clearly superior, but mostcommonly used regimens contain cytosine arabinosidewith any of an anthracycline, etoposide and ⁄ or fludara-bine. The median number of chemotherapy courses inmost studies is two (one induction and one consolidation)and patients rarely tolerate more than this. In all otherhigh-risk MDS patients (namely those for whom intensivechemotherapy alone is not recommended), intensiveremission-induction chemotherapy (two courses) shouldbe offered only if stem cell transplantation is proposed asconsolidation (Fig 3).
Supportive care ⁄ investigational therapy. If patients do notfall into any category for which chemotherapy ± SCT isrecommended they should be offered supportive care orinvestigational therapies within clinical research protocols.
USEFUL WEB SITES
http://www.aamds.orghttp://www.mds-foundation.org/http://www.leukaemia-research.org.uk
USEFUL TELEPHONE NUMBERS
Leukaemia Research Fund +44 (0)207 12421488.
CONFLICTS OF INTEREST
Meeting expenses were covered by support from Janssen-Cilag. Dr Stephen Kelsey became an employee of Phar-macia Upjohn during the guideline preparation process.Dr Culligan and Professor Mufti are members of theROCHE Steering Group for the treatment of cancer-relatedanaemia.
DISCLAIMER
Whilst the advice and information contained in thisguideline are believed to be true and accurate at the timeof going to press, neither the authors nor the publisher canaccept any legal responsibility or liability for any errors oromissions that may be made.
NOTE ADDED IN PROOF
A randomized study of azacytidine versus supportive carehas demonstrated a probable survival advantage andreduced AML transformation for MDS patients randomizedto receive azacytidine (Silverman et al, Journal of ClinicalOncology, 2002, 20, 2429–2440).
David Bowen1
Dominic Culligan2
Simon Jowitt3
Stephen Kelsey4
*
Ghulam Mufti5
David Oscier6
Jane Parker5
of the UK MDS
Guidelines Group
1Molecular and Cellular Pathology,Ninewells Hospital, Dundee,2Aberdeen Royal Infirmary,Aberdeen, 3Stepping HillHospital, Stockport,4Department of Oncology, St.Bartholomews and Royal LondonMDS, London, 5Department ofHaematological Medicine, King’sCollege of Medicine and Dentistry,London, and 6Royal BournemouthHospital, Bournemouth, UK*Present address: Genetech, Inc.,South San Francisco, CA, USA
REFERENCES
Ancliff, P.J. & Machin, S.J. (1998) Trigger factors for prophylactic
platelet transfusion. Blood Reviews, 12, 234–238.
Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman,
H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D.,
Doney, K., Martin, P.J., Sanders, J.E., Sullivan, K.M., Thomas,
E.D., Witherspoon, R.P., Hansen, J.A. & Storb, R. (1993) Allo-
geneic bone marrow transplantation for 93 patients with mye-
lodysplastic syndrome. Blood, 82, 677–681.
Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti,
C., Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T.R.,
Clift, R.A., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J.,
Matthews, D.C., Sanders, J.E., Shulman, H., Sullivan, K.M.,
Witherspoon, R.P. & Storb, R. (1996) Allogeneic marrow
transplantation for refractory anemia: a comparison of two pre-
parative regimens and analysis of prognostic factors. Blood, 87,
51–58.
Anderson, J.E., Gooley, T.A., Schoch, G., Anasetti, C., Bensinger,
W.I., Clift, R.A., Hansen, J.A., Sanders, J.E., Storb, R. &
Appelbaum, F.R. (1997) Stem cell transplantation for secondary
acute myeloid leukemia: evaluation of transplantation as initial
therapy or following induction chemotherapy. Blood, 89, 2578–
2585.
Appelbaum, F.R. & Anderson, J. (1998) Allogeneic bone marrow
transplantation for myelodysplastic syndrome: outcomes analysis
according to IPSS score. Leukemia, 12, s25–s29.
Aul, C., Gattermann, N. & Schneider, W. (1991) Treatment of
advanced myelodysplastic syndromes with recombinant inter-
feron-alpha 2b. European Journal of Haematology, 46, 11–16.
Bain, B.J. (1996) The bone marrow aspirate of healthy subjects.
British Journal of Haematology, 94, 206–209.
Barrett, A.J., Molldrem, J.J., Saunthararajah, Y., Caples, M. &
Young, N.S. (1998) Prolonged transfusion independence
and disease stability in patients with myelodysplastic
syndrome (MDS) responding to antithymocyte globulin (ATG).
Blood, 92, 2932.
Bennett, J.M., Catovsky, M.T., Daniel, G., Flandrin, D.A.G., Galton,
H.R. & Sultan, C. (1982) Proposals for the classification of the
myelodysplastic syndromes. British Journal of Haematology, 51,
189–199.
Bourantas, K.L., Tsiara, S. & Christou, L. (1995) Treatment of 34
patients with myelodysplastic syndromes with 13-CIS retinoic
acid. European Journal of Haematology, 55, 235–239.
Bowen, D.T. & Hellstrom-Lindberg, E. (2001) Best supportive care
for the anaemia of myelodysplasia: inclusion of recombinant
erythropoietin therapy? Leukemia Research, 25, 19–21.
Guideline 197
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Bowen, D.T., Denzlinger, C., Brugger, W., Culligan, D., Gelly, K.,
Adlakha, S., Groves, M., Hepburn, M. & Kanz, L. (1998) Poor
response rate to a continuous schedule of Amifostine therapy for
�low ⁄ intermediate risk� myelodysplastic patients. British Journal of
Haematology, 103, 785–787.
Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A.,
Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone,
R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. &
Greenberg, P.L. (2000) Report of an international working group
to standardize response criteria for myelodysplastic syndromes.
Blood, 96, 3671–3674.
Clark, R.E., Jacobs, A., Lush, C.J. & Smith, S.A. (1987) Effect of
13-cis-retinoic acid on survival of patients with myelodysplastic
syndrome. Lancet, 1, 763–765.
Cotter, P.D., May, A., Fitzsimons, E.J., Houston, T., Woodcock, B.E.,
Al Sabah, A.I., Wong, L. & Bishop, D.F. (1995) Late-onset
X-linked sideroblastic anemia. Missense mutations in the ery-
throid delta-aminolevulinate synthase (ALAS2) gene in two
pyridoxine-responsive patients initially diagnosed with acquired
refractory anemia and ringed sideroblasts. Journal of Clinical
Investigations, 96, 2090–2096.
Deeg, H.J., Shulman, H.M., Anderson, J.E., Bryant, E.M., Gooley,
T.A., Slattery, J.T., Anasetti, C., Fefer, A., Storb, R. & Appelbaum,
F.R. (2000) Allogeneic and syngeneic marrow transplantation
for myelodysplastic syndrome in patients 55–66 years of age.
Blood, 95, 1188–1194.
Demetri, G.D., Kris, M., Wade, J., Degos, L. & Cella, D. (1998)
Quality-of-life benefit in chemotherapy patients treated with
epoetin alfa is independent of disease response or tumor type:
results from a prospective community oncology study. Journal of
Clinical Oncology, 16, 3412–3425.
Denzlinger, C., Bowen, D., Benz, D., Gelly, K., Brugger, W. & Kanz,
L. (2000) Low-dose melphalan induces favourable responses in
elderly patients with high-risk myelodysplastic syndromes or
secondary acute myeloid leukaemia. British Journal of Haematol-
ogy, 108, 93–95.
Di Raimondo, F., Longo, G., Cacciola, Jr, E., Milone, G., Palumbo,
G.A., Cacciola, R.R., Alessi, M. & Giustolisi, R. (1996) A good
response rate to recombinant erythropoietin alone may be
expected in selected myelodysplastic patients. A preliminary
clinical study. European Journal of Haematology, 56, 7–11.
Dunn, D.E., Tanawattanacharoen, P., Boccuni, P., Nagakura, S.,
Green, S.W., Kirby, M.R., Kumar, M.S., Rosenfeld, S. & Young,
N.S. (1999) Paroxysmal nocturnal hemoglobinuria cells in
patients with bone marrow failure syndromes. Annals of Internal
Medicine, 131, 401–408.
Elias, L., Hoffman, R., Boswell, S., Tensen, L. & Bonnem, E.M.
(1987) A trial of recombinant alpha 2 interferon in the
myelodysplastic syndromes. I. Clinical results. Leukemia, 1,
105–110.
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S. & Keating,
M. (1997) Effect of diagnosis (refractory anemia with excess
blasts, refractory anemia with excess blasts in transformation,
or acute myeloid leukemia [AML]) on outcome of AML-type
chemotherapy. Blood, 90, 2969–2977.
Franchini, M., Gandini, G., de Gironcoli, M., Vassanelli, A., Borgna-
Pignatti, C. & Aprili, G. (2000) Safety and efficacy of sub-
cutaneous bolus injection of deferoxamine in adult patients with
iron overload. Blood, 95, 2776–2779.
Galvani, D.W., Nethersell, A.B. & Cawley, J.C. (1988) Alpha-inter-
feron in myelodysplasia; clinical observations and effects on NK
cells. Leukemia Research, 12, 257–262.
Germing, U., Gattermann, N., Strupp, C., Aivado, M. & Aul, C.
(2000a) Validation of the WHO proposals for a new classification
of primary myelodysplastic syndromes: a retrospective analysis of
1600 patients. Leukemia Research, 24, 983–992.
Germing, U., Gattermann, N., Aivado, M., Hildebrandt, B. & Aul, C.
(2000b) Two types of acquired idiopathic sideroblastic anaemia
(AISA): a time-tested distinction. British Journal of Haematology,
108, 724–728.
Gisslinger, H., Chott, A., Linkesch, W., Fritz, E. & Ludwig, H. (1990)
Long-term alpha-interferon therapy in myelodysplastic syn-
dromes. Leukemia, 4, 91–94.
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S.
& Vadhanraj, S. (1997) Impact of therapy with epoetin alfa on
clinical outcomes in patients with nonmyeloid malignancies
during cancer chemotherapy in community oncology practice.
Journal of Clinical Oncology, 15, 1218–1234.
Greenberg, P., Cox, C., Lebeau, M.M., Fenaux, P., Morel, P., Sanz,
G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K.,
Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International
scoring system for evaluating prognosis in myelodysplastic
syndromes (Erratum in Blood 1998, 91, 1100). Blood 89,
2079–2088.
Greenberg, P., Anderson, J.E., de Witte, T., Estey, E., Fenaux, P.,
Gupta, P., Hamblin, T., Hellstrom-Lindberg, E., List, A., Mufti, G.,
Neuwirtova, R., Ohyashiki, K., Sanz, G., Sanz, M., Oscier, D.,
Willman, C. & Members of the International MDS Study Group
(2000) Problematic WHO reclassification of myelodysplastic
syndromes. Journal of Clinical Oncology, 18, 3446–3452.
Grossi, A., Fabbri, A., Santini, V., Leoni, F., Nozzoli, C., Longo, G.,
Pagliai, G., Ciolli, S. & Rossi, F.P. (2000) Amifostine in the
treatment of low–risk myelodysplastic syndromes. Haematologica,
85, 367–371.
Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink,
H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World
Health Organization classification of neoplastic diseases of the
hematopoietic and lymphoid tissues: report of the Clinical
Advisory Committee meeting, Airlie House, Virginia, November
1997. Journal of Clinical Oncology, 17, 3835–3849.
Hellstrom Lindberg, E. (1995) Efficacy of erythropoietin in the
myelodysplastic syndromes: a meta-analysis of 205 patients from
17 studies. British Journal of Haematology, 89, 67–71.
Hellstrom Lindberg, E., Robert, K.H., Gahrton, G., Lindberg, G.,
Forsblom, A.M., Kock, Y. & Ost, A. (1992) A predictive model for
the clinical response to low-dose ara-C: a study of 102 patients
with myelodysplastic syndromes or acute leukaemia. British
Journal of Haematology, 81, 503–511.
Hellstrom Lindberg, E., Birgegard, G., Carlsson, M., Carneskog, J.,
Dahl, I.M., Dybedal, I., Grimfors, G., Merk, K., Tangen, J.M.,
Winqvist, I. & Ost, A. (1993) A combination of granulocyte
colony-stimulating factor and erythropoietin may synergistically
improve the anaemia in patients with myelodysplastic syn-
dromes. Leukemia and Lymphoma, 11, 221–228.
Hellstrom Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G.,
Vardiman, J., Ost, A. & Greenberg, P. (1997) Erythroid response
to treatment with G-CSF plus erythropoietin for the anaemia of
patients with myelodysplastic syndromes: proposal for a pre-
dictive model. British Journal of Haematology, 99, 344–351.
Hellstrom Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M.,
Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-
Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nils-
son-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg,
G., Osterborg, A. & Ost, A. (1998) Treatment of anemia in
myelodysplastic syndromes with granulocyte colony-stimulat-
ing factor plus erythropoietin: results from a randomized phase
II study and long-term follow-up of 71 patients. Blood, 92,
68–75.
198 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Hofmann, W.K., Kell, W.J., Fenaux, P., Castaigne, S., Ganser, A.,
Chomienne, C., Burnett, R., Kowal, C., Hoelzer, D. & Burnett,
A.K. (2000) Oral 9-cis retinoic acid (Alitretinoin) in the treat-
ment of myelodysplastic syndromes: results from a pilot study.
Leukemia, 14, 1583–1588.
Imamura, M., Kobayashi, M., Kobayashi, S., Yoshida, K., Mikuni,
C., Ishikawa, Y., Matsumoto, S., Sakamaki, S., Niitsu, Y., Hinoda,
Y., Yachi, A., Kudoh, T., Chiba, S., Kasai, M., Oka, T., Okuno, A.,
Maekawa, I., Sakurada, K. & Miyazaki, T. (1994) Failure of
combination therapy with recombinant granulocyte colony-
stimulating factor and erythropoietin in myelodysplastic syn-
dromes. Annals of Hematology, 68, 163–166.
Italian Cooperative Study Group (1998) A randomized double-blind
placebo-controlled study with subcutaneous recombinant
human erythropoietin in patients with low-risk myelodysplastic
syndromes. Italian Cooperative Study Group for rHuEpo in
Myelodysplastic Syndromes. British Journal of Haematology, 103,
1070–1074.
Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J. (2001) Tumours of
haematopoietic and lymphoid tissues. World Health Organisation
classification of tumours. IARC Press, Lyon.
Jonasova, A., Neuwirtova, R., Cermak, J., Vozobulova, V.,
Mocikova, K., Siskova, M. & Hochova, I. (1998) Cyclosporin A
therapy in hypoplastic MDS patients and certain refractory
anaemias without hypoplastic bone marrow. British Journal of
Haematology, 100, 304–309.
Kerndrup, G., Bendix-Hansen, K., Pedersen, B., Ellegaard, J. &
Hokland, P. (1987) 13-cis retinoic acid treatment of myelodys-
plastic syndromes. Leukemia Research, 11, 7–16.
Killick, S.B., Marsh, J.C., Cavenagh, J.D., Mijovic, A., Mufti, G.,
Gordonsmith, E.C. & Bowen, D.T. (1999) Antithymocyte globulin
for the treatment of patients with �low risk� myelodysplastic
syndromes. Blood, 94, 1371a.
Koeffler, H.P., Hirji, K. & Itri, L. (1985) 1,25-Dihydroxyvitamin D3:
in vivo and in vitro effects on human preleukemic and leukemic
cells. Cancer Treatment Report, 69, 1399–1407.
Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E., Schulman,
P., Itri, L., Gunter, P. & Besa, E. (1988) Randomized study of
13-cis retinoic acid v placebo in the myelodysplastic disorders.
Blood, 71, 703–708.
Kouides, P.A. & Bennett, J.M. (1996) Morphology and classification
of the myelodysplastic syndromes and their pathologic variants.
Seminars in Hematology, 33, 95–110.
Kuriyama, K., Tomonaga, M., Matsuo, T., Ginnai, I. & Ichimaru, M.
(1986) Diagnostic significance of detecting pseudo-Pelger–Huet
anomalies and micro-megakaryocytes in myelodysplastic syn-
drome. British Journal of Haematology, 63, 665–669.
List, A.F., Brasfield, F., Heaton, R., Glinsmann Gibson, B., Crook, L.,
Taetle, R. & Capizzi, R. (1997) Stimulation of hematopoiesis by
amifostine in patients with myelodysplastic syndrome. Blood, 90,
3364–3369.
Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P.D.,
Loeffler, M., Diehl, V. & Tesch, H. (2000) Treatment of anaemia
in myelodysplastic syndromes with prolonged administration of
recombinant human granulocyte colony-stimulating factor and
erythropoietin. British Journal of Haematology, 109, 367–375.
Mellibovsky, L., Diez, A., Perez-Vila, E., Serrano, S., Nacher, M.,
Aubia, J., Supervia, A. & Recker, R.R. (1998) Vitamin D treat-
ment in myelodysplastic syndromes. British Journal of Haematol-
ogy, 100, 516–520.
Mijovic, A. & Mufti, G.J. (1998) The myelodysplastic syndromes:
towards a functional classification. Blood Review, 12, 73–83.
Miller, K.B., Kim, K., Morrison, F.S., Winter, J.N., Bennett, J.M.,
Neiman, R.S., Head, D.R., Cassileth, P.A., O’Connell, M.J. &
Kyungmann, K. (1992) The evaluation of low-dose cytarabine in
the treatment of myelodysplastic syndromes: a phase-III inter-
group study [published erratum appears in Annals of Hematol-
ogy 1993; 66, 164]. Annals of Hematology, 65, 162–168.
Molldrem, J.J., Caples, M., Mavroudis, D., Plante, M., Young, N.S. &
Barrett, A.J. (1997) Antithymocyte globulin for patients with
myelodysplastic syndrome. British Journal of Haematology, 99,
699–705.
Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C.,
Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis
has strong independent prognostic value in de novo myelodys-
plastic syndromes and can be incorporated in a new scoring
system: a report on 408 cases. Leukemia, 7, 1315–1323.
Morel, P., Declercq, C., Hebbar, M., Bauters, F. & Fenaux, P. (1996)
Prognostic factors in myelodysplastic syndromes: critical analysis
of the impact of age and gender and failure to identify a very-low-
risk group using standard mortality ratio techniques. British
Journal of Haematology, 94, 116–119.
Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D.
(1985) Myelodysplastic syndromes: a scoring system with
prognostic significance. British Journal of Haematology, 59, 425–
433.
Murphy, M.F., Wallington, T.B., Kelsey, P., Boulton, F., Bruce, M.,
Cohen, H., Duguid, J., Knowles, S.M., Poole, G. & Williamson,
L.M. (2001) Guidelines for the clinical use of red cell trans-
fusions. British Journal of Haematology, 113, 24–31.
Nand, S., Ellis, T., Messmore, H., Fisher, S.G., Gaynor, E. & Fisher,
R.I. (1992) Phase II trial of recombinant human interferon alpha
in myelodysplastic syndromes. Leukemia, 6, 220–223.
Negrin, R.S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J.,
Krantz, S. & Greenberg, P.L. (1993) Treatment of the anemia of
myelodysplastic syndromes using recombinant human granulo-
cyte colony-stimulating factor in combination with ery-
thropoietin. Blood, 82, 737–743.
Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J.,
Krantz, S. & Greenberg, P.L. (1996) Maintenance treatment of
the anemia of myelodysplastic syndromes with recombinant
human granulocyte colony-stimulating factor and ery-
thropoietin: evidence for in vivo synergy. Blood, 87, 4076–4081.
Nemunaitis, J., Rosenfeld, C., Getty, L., Boegel, F., Meyer, W.,
Jennings, L.W., Zeigler, Z. & Shadduck, R. (1995) Pentoxifylline
and ciprofloxacin in patients with myelodysplastic syndrome. A
phase II trial. American Journal of Clinical Oncology, 18, 189–193.
Nevill, T.J., Fung, H.C., Shepherd, J.D., Horsman, D.E., Nantel, S.H.,
Klingemann, H.G., Forrest, D.L., Toze, C.L., Sutherland, H.J.,
Hogge, D.E., Naiman, S.C., Le, A., Brockington, D.A. & Barnett,
M.J. (1998) Cytogenetic abnormalities in primary myelodys-
plastic syndrome are highly predictive of outcome after allo-
geneic bone marrow transplantation. Blood, 92, 1910–1917.
Nosslinger, T., Reisner, R., Koller, E., Gruner, H., Tuchler, H.,
Nowotny, H., Pittermann, E. & Pfeilstocker, M. (2001) Myelo-
dysplastic syndromes, from French–American–British to World
Health Organization: comparison of classifications on 431
unselected patients from a single institution. Blood, 98, 2935–
2941.
Novitzky, N., Mohamed, R., Finlayson, J. & Du, T.C. (2000)
Increased apoptosis of bone marrow cells and preserved pro-
liferative capacity of selected progenitors predict for clinical
response to anti-inflammatory therapy in myelodysplastic syn-
dromes. Experimental Hematology, 28, 941–949.
Omoto, E., Deguchi, S., Takaba, S., Kojima, K., Yano, T., Katayama,
Y., Sunami, K., Takeuchi, M., Kimura, F., Harada, M. & Kimura,
I. (1996) Low-dose melphalan for treatment of high-risk mye-
lodysplastic syndromes. Leukemia, 10, 609–614.
Guideline 199
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200
Petti, M.C., Latagliata, R., Avvisati, G., Spiriti, M.A., Montefusco, E.,
Spadea, A. & Mandelli, F. (1996) Treatment of high-risk myelo-
dysplastic syndromes with lymphoblastoid alpha interferon.
British Journal of Haematology, 95, 364–367.
Picozzi, Jr, V.J., Swanson, G.F., Morgan, R., Hecht, F. & Greenberg,
P.L. (1986) 13-cis retinoic acid treatment for myelodysplastic
syndromes. Journal of Clinical Oncology, 4, 589–595.
Pippard, M.J. & Weatherall, D.J. (2000) Oral iron chelation therapy
for thalassaemia: an uncertain scene. British Journal of Haema-
tology, 111, 2–5.
Ramos, F., Fernandez-Ferrero, S., Suarez, D., Barbon, M., Rodriguez,
J.A., Gil, S., Megido, M., Ciudad, J., Lopez, N., del Canizo, C. &
Orfao, A. (1999) Myelodysplastic syndrome: a search for mini-
mal diagnostic criteria. Leukemia Research, 23, 283–290.
Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., Andrews, C.,
Venugopal, P., Gezer, S., Gregory, S., Loew, J., Robin, E., Rifkin,
S., Hsu, W.T. & Huang, R.W. (2000) Patients with myelodys-
plastic syndromes benefit from palliative therapy with amifostine,
pentoxifylline, and ciprofloxacin with or without dex-
amethasone. Blood, 95, 1580–1587.
Remacha, A.F., Arrizabalaga, B., Villegas, A., Manteiga, R., Calvo,
T., Julia, A., Fernandez, F.I., Gonzalez, F.A., Font, L., Junca, J., del
Arco, A., Malcorra, J.J., Equiza, E.P., de Mendiguren, B.P. &
Romero, M. (1999) Erythropoietin plus granulocyte colony-
stimulating factor in the treatment of myelodysplastic syn-
dromes. Identification of a subgroup of responders. The Spanish
Erythropathology Group. Haematologica, 84, 1058–1064.
Rodriguez, J.N., Dieguez, J.C., Muniz, R., Martino, M.L., Fernandez-
Jurado, A., Amian, A., Canavate, M. & Prados, D. (1994) Human
recombinant erythropoietin in the treatment of myelodysplastic
syndromes anemia. Meta-analytic study. Sangre (Barcelona), 39,
435–439.
Rose, E.H., Abels, R.I., Nelson, R.A., Mccullough, D.M. & Lessin, L.
(1995) The use of rHuEpo in the treatment of anemia related
to myelodysplasia (MDS). British Journal of Haematology, 89,
831–837.
Santini, V. & Ferrini, P.R. (1998) Differentiation therapy of mye-
lodysplastic syndromes: fact or fiction? British Journal of Haema-
tology, 102, 1124–1138.
Sanz, G.F., Sanz, M.A., Vallespı, T., Canizo, M.C., Torrabadella, M.,
Garcıa, S., Irriguible, D. & San Miguel, J.F. (1989) Two regression
models and a scoring system for predicting survival and planning
treatment in myelodysplastic syndromes: a multivariate analysis
of prognostic factors in 370 patients. Blood, 74, 395–408.
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M.,
Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel,
S., Amar, A., Brautbar, C., Ben Tal, O., Eldor, A. & Or, R. (1998)
Nonmyeloablative stem cell transplantation and cell therapy as
an alternative to conventional bone marrow transplantation
with lethal cytoreduction for the treatment of malignant and
nonmalignant hematologic diseases. Blood, 91, 756–763.
Stasi, R., Brunetti, M., Bussa, S., Conforti, M., Digiulio, C., Crescenzi,
A., Terzoli, E., Vecchione, A. & Pagano, A. (1997a) Response to
recombinant human erythropoietin in patients with myelodys-
plastic syndromes. Clinical Cancer Research, 3, 733–739.
Stasi, R., Brunetti, M., Bussa, S., Conforti, M., Martin, L.S., La Presa,
M., Bianchi, M., Parma, A. & Pagano, A. (1997b) Serum levels of
tumour necrosis factor-alpha predict response to recombinant
human erythropoietin in patients with myelodysplastic syn-
drome. Clinical Laboratory Haematology, 19, 197–201.
Stone, R.M., Spriggs, D.R., Arthur, K.A., Mayer, R.J., Griffin, J. &
Kufe, D.W. (1993) Recombinant human gamma interferon
administered by continuous intravenous infusion in acute mye-
logenous leukemia and myelodysplastic syndromes. American
Journal of Clinical Oncology, 16, 159–163.
Sutton, L., Chastang, C., Ribaud, P., Jouet, J.P., Kuentz, M., Attal,
M., Reiffers, J., Tigaud, J.M., Rio, B., Dauriac, C., Legros, M.,
Dreyfus, F., Lioure, B., Troussard, X., Milpied, N., Witz, F., Oriol,
P., Cahn, J.Y., Michallet, M., Gluckman, E., Ifrah, N., Pico, J.L.,
Vilmer, E. & Leblond, V. (1996) Factors influencing outcome in
de novo myelodysplastic syndromes treated by allogeneic bone
marrow transplantation: a long-term study of 71 patients Societe
Francaise de Greffe de Moelle. Blood, 88, 358–365.
Tricot, G., Wolf-Peeters, C., Vlietinck, R. & Verwilghen, R.L. (1984)
Bone marrow histology in myelodysplastic syndromes. II. Prog-
nostic value of abnormal localization of immature precursors in
MDS. British Journal of Haematology, 58, 217–225.
Tuzuner, N., Cox, C., Rowe, J.M. & Bennett, J.M. (1994) Bone
marrow cellularity in myeloid stem-cell disorders: impact of age
correction. Leukemia Research, 18, 559–564.
Tuzuner, N., Cox, C., Rowe, J.M., Watrous, D. & Bennett, J.M.
(1995) Hypocellular myelodysplastic syndromes (MDS): new
proposals. British Journal of Haematology, 91, 612–617.
Visani, G., Tosi, P., Manfroi, S., Ottaviani, E., Finelli, C., Cenacchi,
A., Bendandi, M. & Tura, S. (1995) All-trans retinoic acid in the
treatment of myelodysplastic syndromes. Leukemia and Lymphoma,
19, 277–280.
Wattel, E., Guerci, A., Hecquet, B., Economopoulos, T., Copplestone,
A., Mahe, B., Couteaux, M.E., Resegotti, L., Voglova, V.,
Foussard, C., Pegourie, B., Michaux, J.J., Deconinck, E., Stoppa,
A.M., Mufti, G., Oscier, D. & Fenaux, P. (1996) A randomized
trial of hydroxyurea versus vp16 in adult chronic myelomono-
cytic leukemia. Blood, 88, 2480–2487.
Wattel, E., debotton, S., Lai, J.L., Preudhomme, C., Lepelley, P.,
Bauters, F. & Fenaux, P. (1997) Long-term follow-up of de novo
myelodysplastic syndromes treated with intensive chemotherapy:
incidence of long-term survivors and outcome of partial
responders. British Journal of Haematology, 98, 983–991.
Wijermans, P., Lubbert, M., Verhoef, G., Bosly, A., Ravoet, C.,
Andre, M. & Ferrant, A. (2000) Low-dose 5-aza-2¢-deo-
xycytidine, a DNA hypomethylating agent, for the treatment
of high-risk myelodysplastic syndrome: a multicenter phase II
study in elderly patients. Journal of Clinical Oncology, 18, 956–
962.
de Witte, T., van Biezen, A., Hermans, J., Labopin, M., Runde, V.,
Or, R., Meloni, G., Mauri, S.B., Carella, A., Apperley, J.,
Gratwohl, A. & Laporte, J.P. (1997) Autologous bone marrow
transplantation for patients with myelodysplastic syndrome
(MDS) or acute myeloid leukemia following MDS. Chronic and
Acute Leukemia Working Parties of the European Group
for Blood and Marrow Transplantation. Blood, 90,
3853–3857.
Keywords: myelodysplastic syndrome, guidelines, manage-ment, diagnosis.
200 Guideline
� 2003 Blackwell Publishing Ltd, British Journal of Haematology 120: 187–200